Should You Buy Atara Biotherapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Atara Biotherapeutics, Inc. (ATRA) scores 5.4/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $9.44, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 4 of 7 CirclFi valuation models project upside for Atara Biotherapeutics, Inc. (ATRA) at $9.44 — the model consensus leans bullish, with a Quality Score of 5.4/10 and Value-Trap risk of 35/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Atara Biotherapeutics, Inc. (ATRA) in 2026?
What Is the Bull Case vs the Bear Case for Atara Biotherapeutics, Inc. (ATRA)?
| Bull case — $45.83 target (+385.5%) | Bear case — $5.17 target (-45.2%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $9.44 and the median fair value of $24.80 implies +162.7% upside potential. | According to the CirclFi Quality of Company (QOC) framework, Atara Biotherapeutics, Inc.'s score of 5.4/10 signals fundamental weaknesses that could undermine the investment thesis. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $45.83 (+385.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $5.17 (-45.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: gene therapy and cell therapy innovation could provide meaningful support for Atara Biotherapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +430.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Atara Biotherapeutics, Inc. and its Biotechnology peers. |
How Does ATRA Compare to Its Biotechnology Peers?
Valuation data pages: RVMD · NBP · HYFT · HELP · GOSS · HYPD · TELO · ALZN · INSM · EXEL · INCY
Which Other Stocks Score Like ATRA on Quality?
Closest companies to ATRA’s Quality of Company score of 5.4/10, across all industries.
Which Biotechnology Screens Does ATRA Appear In?
So Is Atara Biotherapeutics, Inc. (ATRA) Worth Buying in 2026?
Atara Biotherapeutics, Inc. leans positive in our analysis — 4/7 models bullish, median fair value of $24.80 vs. $9.44, QOC 5.4/10. The case is constructive but not overwhelming, and the 3 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Atara Biotherapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ATRA Stock?
Should I buy ATRA stock right now?
Based on CirclFi's multi-model analysis, 4 of 7 models see upside for ATRA at $9.44. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Atara Biotherapeutics, Inc.?
Key risks include: limited model coverage (7/13 active), reducing analytical confidence; wide model disagreement (786% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ATRA compare to its competitors?
Among Biotechnology peers, ATRA holds a Quality Score of 5.4/10. Comparable companies include RVMD (QOC 5.4), NBP (QOC 5.4), HYFT (QOC 5.4). The relative ranking helps investors identify whether ATRA offers better fundamental quality than alternatives in the same sector.
Is ATRA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATRA's Quality Score of 5.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ATRA at?
CirclFi does not provide target buy prices or price alerts. However, our 7 active models produce fair value estimates ranging from $5.17 to $45.83. At $9.44, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ATRA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad